Market Overview - The Hong Kong stock market opened slightly lower on October 6, with the Hang Seng Index at 27,003 points, down 137 points, a decline of 0.50% [1] - The Hang Seng Technology Index reported 6,548.80 points, down 74.05 points, a decrease of 1.12% [4] New IPO - Xuan Bamboo Biotechnology-B (02575.HK) is conducting an IPO from October 6 to October 10, planning to globally offer 67.335 million shares, with 10% allocated for Hong Kong and 90% for international sales, plus a 15% over-allotment option, at a price of HKD 11.6 per share [3] - The stock is expected to start trading on the Hong Kong Stock Exchange on October 15 [3] - Xuan Bamboo is an innovative Chinese biopharmaceutical company with over ten drug assets in active development, targeting digestive diseases, tumors, and non-alcoholic fatty liver disease (NASH) [3] Sector Performance - Technology stocks generally declined, with NetEase opening down over 2% but later recovering; Bilibili, Lenovo, Alibaba, JD.com, and Baidu all fell over 1%, while Tencent saw a rise of over 1% [3] - Gold stocks experienced gains, with China Silver Group up over 10% and Zifeng Gold up over 5% [3] - Semiconductor stocks were active, with Hongguang Semiconductor rising over 1% [3] - Automotive stocks weakened, with Xpeng Motors down over 4% [3] Market Sentiment and Forecast - According to Industrial Securities, the current Hong Kong market is driven by three favorable factors: rising policy expectations, bottoming earnings recovery, and a loose liquidity environment, which may enhance market risk appetite [5] - The Federal Reserve has entered a rate-cutting cycle, with expectations for further cuts in October, creating a more favorable external environment for Hong Kong stocks [5] - Guosen Securities noted that the Fed's dovish stance improves overseas liquidity, and the unusual rise in Hong Kong stocks amid earnings downgrades in August and September indicates a systematic change in risk premium, opening up further upside potential for the market [5] - The weighted risk premium assessment has led to an upward revision of the 2025 Hang Seng Index target to 29,000 points [5]
港股速报 | 港股低开 轩竹生物今起招股